Cancer Immunology and Immunotherapy
Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
- 1st Edition - August 18, 2021
- Imprint: Academic Press
- Editors: Mansoor M. Amiji, Lara Scheherazade Milane
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 3 9 7 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 6 3 7 - 6
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncolog… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDelivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited.
Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches.
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.
- Comprehensive treaty covering all aspects of immuno-oncology (IO)
- Novel strategies for delivery of IO therapeutics and vaccines
- Forecasting on the future of nanotechnology and drug delivery for IO
Scientists and clinicians working in research and development of IO therapeutics and vaccines. The book will also serve a useful guide for graduate students and postdoctoral associate working in this field. Can be useful as a teaching tool in Advanced Drug Delivery, Biomaterials, and Cancer Biology and Therapeutics courses taught to both undergraduate and graduate students
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- Preface
- Acknowledgments
- Chapter One: The hallmarks of cancer and immunology
- Abstract
- 1: Introduction
- 2: Activating invasion and metastasis
- 3: Resistance to cell death
- 4: Evading growth suppression and sustaining proliferative signaling
- 5: Genome instability and mutation and replicative immortality
- 6: Angiogenesis
- 7: Avoiding immune destruction and tumor-promoting inflammation
- 8: Deregulated energetics
- 9: Plasticity, tumor heterogeneity, quiescence, and stemness
- 10: Conclusion
- Chapter Two: Innate and adaptive immunity in cancer
- Abstract
- 1: Introduction
- 2: Innate immunity
- 3: Effector mechanisms and immunotherapies modulating innate immunity pathway
- 4: Adaptive immunity
- 5: Recognition of antigens
- 6: Costimulatory signals
- 7: Adaptive immune activation
- 8: Adaptive immune regulation
- 9: Humoral mediated immunity
- 10: Immune suppression and cancer progression
- 11: Treatments modulating the adaptive immune system
- 12: Conclusion
- Chapter Three: Inflammation and cancer
- Abstract
- 1: Introduction
- 2: Similarities and differences between inflammatory responses in “Physiological” conditions and “Inflammation in Cancer”
- 3: Sources of inflammation during tumorigenesis
- 4: Role of inflammation in tumor initiation
- 5: Role of inflammation in tumor progression
- 6: Role of inflammation in tumor metastasis
- 7: Inflammation elicited due to cancer therapy
- 8: Conclusions
- Chapter Four: Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors
- Abstract
- 1: Introduction
- 2: VGSC expression and function in cells of the immune system
- 3: Potential of VGSC (nNav1.5) expression in immunotherapy
- 4: Conclusions and future perspectives
- Chapter Five: Immunoediting and cancer priming
- Abstract
- 1: Introduction
- 2: Cancer-immunity cycle
- 3: Tumors escape immunosurveillance through immunoediting
- 4: Human leukocyte antigen (HLA) loss and immune escape in lung cancer evolution
- 5: Heterogenous immunoediting in lung cancer
- 6: Neoantigen derived from mutation
- 7: Treg and tumor immunity
- 8: Tumor-associated macrophages (TAMs) and tumor immunity
- 9: Conclusions
- Chapter Six: Metabolic reprogramming and immunity in cancer
- Abstract
- 1: Introduction
- 2: Cancer immunity and immunotherapy
- 3: Metabolic reprogramming and immunometabolism
- 4: Conclusion and perspectives
- Chapter Seven: Epigenetic programming of the immune responses in cancer
- Abstract
- 1: Introduction
- 2: Epigenetic mechanisms
- 3: Overview of cancer-immunity cycle
- 4: Epigenetic regulation of immune cells in the tumor microenvironment
- 5: Epigenetic barriers to cancer immunotherapy
- 6: Epigenetic reprogramming of immune cells in the tumor microenvironment
- Chapter Eight: Cellular therapeutics in immuno-oncology
- Abstract
- 1: Introduction
- 2: Chimeric antigen receptor (CAR)
- 3: CAR-T cells
- 4: CAR-NK cells
- 5: CAR-M cells
- 6: Conclusions
- Chapter Nine: T-cell engaging bispecific antibody therapy
- Abstract
- 1: Inherently active T-cell engagers
- 2: The challenges of targeting solid tumor indications
- 3: Next-generation TCEs
- 4: Potential mechanisms of resistance to TCEs
- 5: The limitations of preclinical in vivo efficacy models
- 6: TCEs targeting solid tumors in the clinic
- Chapter Ten: Role of microbiome in cancer immunotherapy
- Abstract
- Conflict of Interest
- 1: Introduction
- 2: Main immunotherapy approaches: From the past to nowadays
- 3: A new emerging actor in cancer immunotherapy response: The human microbiome
- 4: Crosstalk between the microbiome and immunity in cancer
- 5: The “microbiome-immunity axis” influences the effectiveness of cancer immunotherapy
- 6: Microbiota shaping: From molecular immunotherapy to “eco-immunotherapy”
- 7: How the holobiont perspective can reshape our approach to cancer immunotherapy
- 8: Conclusions
- Chapter Eleven: STING pathway and modulation for cancer immunotherapy
- Abstract
- 1: Introduction
- 2: cGAS–STING signaling pathway in cancer
- 3: Targeting the STING pathway for cancer immunotherapy
- 4: Drug delivery systems for STING agonists
- 5: Summary and outlook
- Chapter Twelve: Oncolytic viruses in immunotherapy
- Abstract
- 1: Introduction—Oncolytic viroimmunotherapy
- 2: A brief history of oncolytic viruses
- 3: Overview of oncolytic virotherapy
- 4: Oncolytic virus safety and efficacy
- 5: Viral gene expression, replication and oncolysis
- 6: Immune-mediated antitumor activity
- 7: Oncolytic viruses as gene expression platforms
- 8: Oncolytic virus platforms and clinical trials
- 9: Conclusion
- Chapter Thirteen: Comparison of therapeutic strategies for immuno-oncology
- Abstract
- 1: Introduction
- 2: The immunological response
- 3: The intrinsic immune response within a cancer cell
- 4: The innate immune response
- 5: The adaptive immune response
- 6: B-cell immunotherapy
- 7: Summary
- Chapter Fourteen: Intrinsic and acquired cancer immunotherapy resistance
- Abstract
- 1: Introduction
- 2: Tumor microenvironment
- 3: Cancer immunotherapies
- 4: Mechanisms of resistance against cancer immunotherapies
- 5: Therapeutic approaches to overcome resistance
- 6: Conclusions, challenges, and future perspectives
- Chapter Fifteen: Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies
- Abstract
- 1: Introduction
- 2: Overview of immunotoxicity with immuno-oncology therapies
- 3: Current practices and challenges in preclinical translation of IrAEs with immuno-oncology therapy
- 4: Regulatory guidance for safe clinical dosing with immuno-oncology therapies
- 5: Preclinical mitigation strategies for translatable prediction of IrAEs
- 6: Alternative approach to defining safe clinical starting doses with immuno-oncology therapy
- 7: Conclusion
- Index
- Edition: 1
- Published: August 18, 2021
- Imprint: Academic Press
- No. of pages: 548
- Language: English
- Paperback ISBN: 9780128233979
- eBook ISBN: 9780128236376
MA
Mansoor M. Amiji
Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable.
Affiliations and expertise
Distinguished Professor and Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USALM
Lara Scheherazade Milane
Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouvé College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.
Affiliations and expertise
Assistant Teaching Professor in Biotechnology, Bouve College of Health Sciences, Northeastern University, USARead Cancer Immunology and Immunotherapy on ScienceDirect